Barish Ozdamar's practice focuses on intellectual property litigation and patent prosecution matters in the pharmaceutical, biotechnology and medical device industries. He has counseled and assisted clients in District Court litigation, at proceedings before the Patent Trial and Appeal Board (PTAB), and in arbitration. Dr. Ozdamar has extensive experience representing life science clients over a wide range of matter types including Biologics and Hatch-Waxman litigation, Inter Partes Review proceedings, transactional and pre-litigation diligence, FTO and landscape analysis, patentability assessments, as well as patent portfolio management. His practice covers several technical areas including personalized medicine, gene therapy and delivery vehicles (e.g., CRISPR, AAV and LNPs), vaccines, antibody and small molecule design/therapeutics, diagnostics (including cell-free DNA based applications), and next-generation sequencing technologies.

Prior to joining the firm, Dr. Ozdamar was a Post-Doctoral Fellow at Cornell University Weill Medical College, where he examined the role of cholesterol metabolism in atherosclerosis and stroke. During his graduate tenure at the University of Toronto, Dr. Ozdamar's research focused on cancer biology and molecular pathways regulating tumor metastasis. He has also been the recipient of Post-Doctoral Fellowships from the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. Dr. Ozdamar's publication record includes four authorships in the journal Science.


  • Obtained a favorable pre-trial result for our client, a large medical device company, in connection with a gene expression platform.
  • Successful District Court representation of a leading medical diagnostic company in a matter relating to fetal genetic testing.
  • Desired outcome for multi-national pharmaceutical client faced with an infringement suit relating to antibody and screening technologies.
  • Represented and obtained a favorable pre-trial outcome for a large biotechnology company challenged by multiple generic biologic entrants against an antibody product.
  • Successful representation of a large pharmaceutical client in an ANDA litigation relating to a small-molecule anti-cancer compound.
  • Desired outcome for a large pharmaceutical client in Swiss arbitration proceedings relating to genetic screening technologies.


  • Selected for inclusion in Best Lawyers: Ones to Watch for intellectual property law (2024).
  • Canadian Institutes of Health Research Post-Doctoral Fellowship.
  • Heart and Stroke Foundation of Canada Post-Doctoral Fellowship.
  • Canadian Institutes of Health Research Doctoral Award.

Insights & News


  • Education

    • JD, Fordham University School of Law, 2011

    • Post-Doctoral Fellow, Biochemistry, Cornell University Weill Graduate School of Medical Sciences, 2007

    • Post-Doctoral Fellow, Cell Biology, 2006

      The Hospital for Sick Children, Toronto, Canada
    • PhD, Medical Genetics, University of Toronto, 2005

      Samuel Lunenfeld Research Institute, Mt. Sinai Hospital
    • BSc (Hons), York University, 1998

  • Admissions

    • New York

    • US Patent and Trademark Office

  • Languages

    • French

    • Turkish